Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: A meta-analysis

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 1, 2014, Pages 14-24

  Park, C ^a   Jiang, S ^a   Lawson, K A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

boceprevir; hepatitis C; meta analysis; protease inhibitors; telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRURITUS; QUALITY CONTROL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK FACTOR; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT;

BOCEPREVIR; HEPATITIS C; META-ANALYSIS; PROTEASE INHIBITORS; TELAPREVIR;

GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROLINE;

EID: 84891832915     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12106     Document Type: Article

References (46)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int, 2009; 29 (Suppl. 1): 74-81.
2. U.S. Centers for Disease Control. Hepatitis C information for health professionals. [Online]. Available at: http://www.cdc.gov/hepatitis/HCV/index. htm (accessed 8 March 2013).
3. Alter HJ, Seeff LB,. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis, 2000; 20: 17-35.
4. Camma C, Giunta M, Andreone P, Craxi A,. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol, 2001; 34: 593-602.
5. Davis GL, Albright JE, Cook SF, Rosenberg DM,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl, 2003; 9: 331-338.
6. Verna EC, Brown RS Jr,. Hepatitis C virus and liver transplantation. Clin Liver Dis, 2006; 10: 919-940.
7. Nainan OV, Alter MJ, Kruszon-Moran D, et al,. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology, 2006; 131: 478-484.
8. Simmonds P, Bukh J, Combet C, et al,. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005; 42: 962-973.
9. Liapakis A, Jacobson I,. Telaprevir user's guide. Clin Liver Dis, 2011; 15: 555-571.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 2009; 49: 1335-1374.
11. Dienstag JL, McHutchison JG,. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology, 2006; 130: 225-230.
12. Haider SI, Ahmad J,. Update of old and emerging therapies in chronic hepatitis C. J Pak Med Assoc, 2011; 61: 1226-1230.
13. Schiff ER,. Diagnosing and treating hepatitis C virus infection. Am J Manag Care, 2011; 17 (Suppl. 4): S108-S115.
14. Herrine SK,. Schiff's diseases of the liver. Gastroenterology, 1999; 116: 1501-1502.
15. Di Bisceglie AM, Hoofnagle JH,. Optimal therapy of hepatitis C. Hepatology, 2002; 36 (Suppl. 1): S121-S127.
16. McHutchison JG, Lawitz EJ, Shiffman ML, et al,. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med, 2009; 361: 580-593.
17. Foote BS, Spooner LM, Belliveau PP,. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother, 2011; 45: 1085-1093.
18. Ramachandran P, Fraser A, Agarwal K, et al,. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther, 2012; 35: 647-662.
19. Shiffman ML, Esteban R,. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? Liver Int, 2012; 32 (Suppl. 1): 54-60.
20. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011; 54: 1433-1444.
21. Boceprevir prescribing information. [Online]. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2011/202258lbl.pdf (accessed 8 March 2013).
22. Victrelis approval history. [Online]. Available at: http://www.drugs.com/ history/victrelis.html (accessed 8 March 2013).
23. Telaprevir prescribing information. [Online]. Available at: www.accessdata.fda.gov/drugsatfda-docs/label/2011/201917lbl.pdf (accessed 8 March 2013).
24. Incivek approval history. [Online]. Available at: http://www.drugs.com/ history/incivek.html (accessed 8 March 2013).
25. Dang SS, Wang WJ, Wang XF, et al,. Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis. Hepatogastroenterology, 2011; 59: 461-468.
26. Qin H, Li H, Zhou X, et al,. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials. Clin Drug Investig, 2012; 32: 665-672.
27. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R,. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med, 2013; 158: 114-123.
28. Cooper CL, Druyts E, Thorlund K, et al,. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag, 2012; 8: 105-130.
29. Cure S, Diels J, Gavart S, Bianic F, Jones E,. Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Curr Med Res Opin, 2012; 28: 1841-1856.
30. Muir AJ, Bornstein JD, Killenberg PG,. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med, 2004; 350: 2265-2271.
31. Jadad AR, Moore RA, Carroll D, et al,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996; 17: 1-12.
32. The Cochrane Collaboration's tool for assessing risk of bias. [Online]. Available at: http://ohg.cochrane.org/sites/ohg.cochrane.org/files/uploads/ Risk%20of%20bias%20assessment%20tool.pdf (accessed 11 May 2013).
33. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002; 21: 1539-1558.
34. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N,. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol, 2012; 56: 78-84.
35. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med, 2011; 364: 2405-2416.
36. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med, 2009; 360: 1839-1850.
37. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med, 2009; 360: 1827-1838.
38. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med, 2011; 364: 2417-2428.
39. McHutchison JG, Manns MP, Muir AJ, et al,. Telaprevir for previously treated chronic HCV infection. N Engl J Med, 2010; 362: 1292-1303.
40. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med, 2011; 364: 1195-1206.
41. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, 2010; 376: 705-716.
42. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med, 2011; 364: 1207-1217.
43. Flamm SL, Lawitz E, Jacobson I, et al,. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol, 2013; 11: 81-87.
44. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS,. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther, 2010; 32: 969-983.
45. Burton MJ, Passarella MJ, McGuire BM,. Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers. South Med J, 2012; 105: 431-436.
46. Cooper C, Lester R, Thorlund K, et al,. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM, 2012; 2013: 153-163.